Sildenafil for the Prevention of Right Heart Failure Following LVAD Implantation

End Stage Heart Failure Clinical Trial

Official title:

Sildenafil for the Prevention of Right Heart Failure Following Continuous-Flow Left Ventricular Assist Device Implantation (The REVAD Study)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03356353
• Other study ID #: RVD102017
• Status: Recruiting
• Phase: Phase 3
• Start date: March 12, 2018
• Est. completion date: January 2022

Study information

• Verified date: April 2021
• Source: University of Calgary
• Contact: Nowell Fine, FRCPC
• Phone: 403-956-3748
• Email: nowell.fine[@]albertahealthservices.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Continuous-flow left ventricular assist devices (LVAD) move blood from the left ventricle (the largest chamber of the heart) to the aorta (the body's main artery) to help the heart better meet the needs of the body and to improve survival for patients with advanced heart failure (HF). The ability of the right ventricle (the large chamber on the right side of the heart) to keep up with the improved blood flow following LVAD greatly effects how well a person does following surgery. It is understood that a high pulmonary artery pressure (pressure in the blood vessel that takes blood from the right side of the heart to the lungs) measured before surgery, indicates that a higher risk of right heart failure exists after LVAD implantation.

This is important because right heart failure after surgery is related to longer intensive care unit (ICU) and hospital stays, increased morbidity (other health problems) including organ failure and worse outcomes following heart transplant, and increased death rates.

Sildenafil (Revatio®) has been approved by Health Canada in the treatment of pulmonary arterial hypertension (high blood pressure in the lungs) in patients with connective tissue disease. Sildenafil has not yet been approved by Health Canada for the treatment of pulmonary hypertension in heart failure. Sildenafil lowers blood pressure in the lungs and lessens the workload of the right ventricle (the right side of the heart). The purpose of this study is to determine if lowering blood pressure in the lungs, in heart failure patients at risk for developing right heart failure after LVAD implant, lowers the incidence of right heart failure, shortens ICU and hospital stays and reduces morbidity (other health problems) and mortality (death rates).

This is an open label, single arm study. Everyone who participates in this study will receive sildenafil before and after LVAD surgery. It is expected that 24 patients who are scheduled to have LVAD implantation for advanced heart failure will be enrolled from 6 sites across Canada. Participants will be followed in the study for about 2 months.

Description:

Initially implanted as a bridge to transplantation, LVADs are increasingly used for the purpose of destination therapy. About 250 patients/year will receive LVAD device therapy in 12 implanting Canadian centres. Outcomes after LVAD implantation are critically dependent on right ventricular (RV) function. Development of right heart failure (RHF) in LVAD patients has a direct effect on mortality and is associated with a prolonged length of intensive care unit (ICU) and hospital admission. RHF in LVAD patients leads to increased morbidity and is associated with worse outcomes after cardiac transplantation. Despite improvements in surgical and medical management the incidence of RHF after LVAD implantation has plateaued at approximately 20-30%. A critical concept in the prevention of post-operative complications involves appropriate patient selection and prophylactic measures directed toward risk factors for development of RHF. To mitigate the risk of RHF after LVAD implantation, many implanting centres are increasingly utilizing pulmonary vasodilating agents in the post-operative period. Despite little evidence to support this approach, the phosphodiesterase-5A (PDE5) inhibitor Sildenafil is now empirically administered for reduction of PVR in some centres after LVAD implantation. Duration of therapy varies but may extend beyond 3 months and in some cases may continue indefinitely or until the time of heart transplant. A small, single-centre, open label study demonstrated that Sildenafil effectively reduced PVR in LVAD patients with persistent pulmonary hypertension post-operatively, however only hemodynamic endpoints were examined. Importantly, the investigation of this strategy was limited to those with elevated PAP, irrespective of their clinical condition or pre-implantation hemodynamic profile. There is a clear need for further research to establish the safety and efficacy of pulmonary vasodilators to either treat or prevent RHF in the LVAD patient population.

The investigators hypothesize that the vasodilatory effects of sildenafil can prevent or reverse the effects of elevated RV afterload and consequent RHF following LVAD implantation, and that preoperative initiation of therapy in an at-risk population is feasible and will be well tolerated. As such, there is a large potential for sildenafil to meet an unmet therapeutic need for patients following LVAD implantation.

The primary objective of this pilot study is to evaluate the tolerability and efficacy of sildenafil therapy initiated prior to and continued after LVAD implantation for the purpose of reducing PVR in patients at increased risk for development of RHF by INTERMACS criteria. The feasibility of introducing sildenafil in this clinical setting along with the ability to reduce PVR will be assessed.

Secondary Objectives: a) To determine the efficacy of sildenafil to reduce the need for prolonged inotropic support and post-operative ICU admission duration b) To determine the tolerability and feasibility of the proposed dosing strategy c) To determine the impact of sildenafil therapy on renal function and systemic arterial blood pressure d) To assess the impact of sildenafil therapy on the likelihood of development of post-operative RHF by INTERMACS criteria

STUDY METHODS:

1. Single-arm, open-label, prospective, multi-centre, interventional, feasibility and efficacy, pilot study of sildenafil in patients undergoing LVAD implantation.

2. This multi (6)-centre, Canadian trial is investigator initiated and industry sponsored. The study design, coordination and conduction and other study tasks including monitoring will be performed by the study investigators.

Following enrolment into the study, subjects will have their data (i.e. weight, blood pressure, pulse, lab work, medications, RHC data, ECG, physical exam), collected as standard-of-care (SOC), included in their study chart. Participants will be started on sildenafil at V1. If tolerated, subjects will be maintained on sildenafil pre and post-LVAD implementation. On day 14 (+/- 2 days) subjects will have a RHC to evaluate right heart function post-LVAD implantation. Subjects will return to the VAD (Ventricular Assist Device) Clinic for regular visits following discharge until day 55 (EOS) for similar data collection. Subjects will keep a daily sildenafil dosage diary from hospital discharge until day 55. Subjects will receive a brief telephone call at day 85 post LVAD implantation to evaluate safety and outcome data.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 24
• Est. completion date: January 2022
• Est. primary completion date: September 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients aged >18 years who are to receive durable (HeartMate II or III, or HeartWare HVAD) LVAD implantation for end-stage HF. Patients with all etiologies of HF will be included.

• Patients identified as having an increased risk for post-operative RHF using pre-operative hemodynamic assessment criteria, defined as the presence of = 1 of the following: i) Central venous pressure (CVP):mean pulmonary capillary wedge pressure (PCWP) ratio = 0.63 ii) RV stroke work index < 300 mmHg/mL/m2 iii) CVP =15 mmHg (CVP must be >8 mmHg if applying one of the other criteria) iv) Pre-operative PVR = 3 Wood Units (240 dynes/cm5/sec)

• Systolic blood pressure = 85 mmHg at study initiation

• Women of childbearing potential must have a negative pregnancy test. Women must not be breast feeding. Heterosexually active women of child bearing potential must use an effective method of contraception during the study.

• Ability to sign informed consent to participate

Exclusion Criteria:

• Preoperative INTERMACS level I or II

• Preoperative systemic hypotension with mean arterial pressure < 60 mmHg

• Planned insertion of RV support device (either temporary or permanent)

• Complex congenital heart disease where PVR measurement is not feasible or reliable (repaired or unrepaired)

• Right sided fixed or dynamic obstruction to blood flow (i.e., pulmonary stenosis) with resting gradient = 10 mmHg.

• Previous organ transplantation

• Preoperative use of any oral pulmonary vasodilator therapy or oral/inhaled/nitrate therapy

• Patients requiring pre-operative hem - or peritoneal dialysis

• Pre-enrollment treatment with other pulmonary dilating agents such as other PDE5 inhibitors, endothelin antagonists, prostacyclin analogues. Use of postoperative nitric oxide will be permitted (although not concomitantly with the study medication) as clinically indicated in the postoperative setting

• Lack of ability to invasively measure right-sided pulmonary pressures

• Refusal or inability to sign informed consent

• Inability to accept preoperative study drug, or known sensitivity or allergy to sildenafil or any of its ingredients, or any other contra-indication to sildenafil as identified by product monograph

• Participation in any other current interventional (drug or device) study

Related Conditions & MeSH terms

• End Stage Heart Failure
• Heart Failure

Intervention

Drug:
• Sildenafil Citrate
20 mg tablets

Locations

Country	Name	City	State
Canada	University of Calgary	Calgary	Alberta
Canada	London Health Sciences Centre	London	Ontario
Canada	University of Ottawa Heart Institute	Ottawa	Ontario
Canada	St. Boniface Hospital	Winnipeg	Manitoba

Sponsors (2)

Lead Sponsor	Collaborator
University of Calgary	Pfizer

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Safety: Drug interruptions	Proportion of patients with temporary or permanent study drug interruptions	From baseline to day 55 (study end)
Other	Safety: Renal	Proportion of patients requiring renal replacement therapy or doubling of serum creatinine	From baseline to day 55 (study end)
Other	Safety: All-cause mortality	All-cause mortality at study end	From enrollment to day 85 (final SAE review)
Other	Safety: Transfusion	Total number of units of packed red cells transfused during hospital stay	From baseline to hospital discharge
Other	Safety: GFR	Greatest percentage increase in glomerular filtration rate from baseline at any time during study	From baseline fo day 55 (study end)
Other	Safety: Mean arterial pressure	Mean arterial pressure	At ICU discharge and at day 55 (study end)
Other	Safety: Symptomatic hypotension	Proportion of patients with > or = 1 episodes of symptomatic hypotension (syncope or orthostatic hypotension)	From baseline to day 55 (study end)
Other	Safety: Liver enzymes	Increase in hepatic enzymes > or = 2x baseline (preoperative) levels	From baseline to day 55 (study end)
Other	Safety: Pump time	Total cardiac surgical bypass pump time	LVAD implantation day
Other	Safety: Adverse drug reactions	Any and all adverse drug reactions	From baseline to day 85 (final SAE review)
Primary	Pulmonary vascular resistance (PVR)	Change in PVR reported in Wood Units as measured invasively via right heart catheterization (RHC)	From baseline to postoperative day 14
Secondary	Right heart failure (RHF)	Proportion of participants experiencing RHF defined as INTERMACS criteria: i) Requirement of continuous-flow right ventricular assist device (RVAD) implantation for hemodynamic support any time prior to study end	From baseline to day 55 (end of study)
Secondary	RHF	Proportion of participants experiencing RHF defined as INTERMACS criteria: ii) Prolonged inotropic support beyond postoperative day 14 directed for clinical RHF	Postoperative day 14 to postoperative day 55 (end of study)
Secondary	RHF	Proportion of participants experiencing RHF defined as INTERMACS criteria: iii) Discontinuation of study drug for the purpose of introduction of additional pulmonary vasodilator for the purpose of treatment of clinical RHF at any time during the study protocol	From baseline to postoperative day 55 (end of study)
Secondary	Inotrope requirement	Proportion of patients requiring any inotrope medication at study end	From baseline to day 55 (study end)
Secondary	ICU	Total number of hours in ICU by study end	From baseline to day 55 (end of study)
Secondary	Hospitalization	Total hospital length of stay by study end	From baseline to day 55 (end of study)